Results 91 to 100 of about 25,543 (277)

Purine Metabolism and Dystonia: Perspectives of a Long‐Promised Relationship

Annals of Neurology, Volume 97, Issue 5, Page 809-825, May 2025.
Purine pool imbalance in purine metabolism disorders, such as Lesch–Nyhan disease, intersects with dystonia pathogenesis. The recent discovery of gain‐of‐function IMPDH2 pathogenic variants in patients with prominent dystonic manifestations provides new insights into the link between dystonia and purinergic system defects.
Ugo Sorrentino, Audrey G. O'Neill, Justin M. Kollman, Hyder A. Jinnah, Michael Zech   +4 more
wiley   +1 more source

Purine Nucleoside Phosphorylase: Allosteric Regulation of a Dissociating Enzyme

Journal of Biological Chemistry, 1991
Purine nucleoside phosphorylase (EC 2.4.2.1) from bovine spleen is a trimeric enzyme that readily dissociates to the monomer. Dilution of enzyme from 20 to 0.02 microgram of protein/ml is accompanied by a greater than 50-fold increase in the specific activity (vtrimer = 0.23 nmol/min/microgram; vmonomer = 12.5 nmol/min/micrograms).
T W, Traut, P A, Ropp, A, Poma
openaire   +5 more sources

Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra‐Terminal Domain Inhibitors

Cancer Science, Volume 116, Issue 5, Page 1392-1404, May 2025.
Our study found that epigenetic changes, particularly histone modifications regulating FGF1, contribute to osimertinib resistance. Targeting these modifications with BET inhibitors may offer new therapeutic strategies. ABSTRACT Osimertinib, a third‐generation EGFR‐tyrosine kinase inhibitor, is the first‐line therapy for lung cancer harboring EGFR ...
Yosuke Miyashita, Ken Tajima, Kenta Izumi, Naohisa Matsumoto, Daisuke Hayakawa, Ikuko Takeda Nakamura, Isana Katayama, Adityo Wibowo, Hironari Matsuda, Wira Winardi, Bagus Radityo Amien, Yoichiro Mitsuishi, Fumiyuki Takahashi, Kohta Nakamura, Ken Uchibori, Noriko Yanagitani, Takuo Hayashi, Kazuya Takamochi, Kenji Suzuki, Ryohei Katayama, Kazuhisa Takahashi   +20 more
wiley   +1 more source

Mycoplasma hyorhinis‐encoded cytidine deaminase efficiently inactivates cytosine‐based anticancer drugs

FEBS Open Bio, 2015
Mycoplasmas may colonize tumor tissue in patients. The cytostatic activity of gemcitabine was dramatically decreased inMycoplasma hyorhinis‐infected tumor cell cultures compared with non‐infected tumor cell cultures.
Johan Vande Voorde, Peter Vervaeke, Sandra Liekens, Jan Balzarini   +3 more
doaj   +1 more source

Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.

Annals of Oncology, 2015
BACKGROUND The use of Escherichia coli purine nucleoside phosphorylase (PNP) to activate fludarabine has demonstrated safety and antitumor activity during preclinical analysis and has been approved for clinical investigation.
E. Rosenthal, T. Chung, W. Parker, P. Allan, L. Clemons, Deborah Lowman, Jeong S. Hong, F. R. Hunt, J. Richman, R. Conry, K. Mannion, W. Carroll, L. Nabell, E. Sorscher   +13 more
semanticscholar   +1 more source

Purine nucleoside phosphorylase in chronic lymphocytic leukemia (CLL) [PDF]

Blood, 1978
Purine nucleoside phosphorylase (PNP), the enzyme schematically next to adenosine deaminase in the purine salvage pathway, has been demonstrated cytochemically in peripheral blood lymphocytes of healthy subjects and chronic lymphocytic leukemia (CLL) patients. The enzyme activity is confined to the cytosol.
J. De Cree, M. Borgers, W. De Cock, M. De Brabander, Herman Verhaegen, G. Geuens, Fred Thoné   +6 more
openaire   +4 more sources

Harnessing nucleotide metabolism and immunity in cancer: a tumour microenvironment perspective

The FEBS Journal, Volume 292, Issue 9, Page 2155-2172, May 2025.
This review explores how changes in nucleotide metabolism affect the tumour microenvironment and immune responses in cancer. Here, we discuss the dual role of nucleotide metabolism in promoting cancer cell growth and shaping immune suppression. We highlight how therapies targeting nucleotide pathways can enhance immunotherapy efficacy, offering new ...
Hadil Suleiman, Alexandra Emerson, Peter M. Wilson, Karl A. Mulligan, Robert D. Ladner, Melissa J. LaBonte   +5 more
wiley   +1 more source

Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. [PDF]

, 2001
We attempt to identify the plasma membrane transporter involved in the uptake of 5'-deoxy-5-fluorouridine (5'-DFUR), an intermediate metabolite of capecitabine.
Casado, F.J. (F. Javier), Fernandez-Veledo, S. (Sonia), Garcia-Manteiga, J.M. (José M.), Guillen-Gomez, E. (Elena), Larrayoz, I.M. (Ignacio M.), LLoberas, J. (Jorge), Lostao, M.P. (María Pilar), Mata, J.F. (Joao F.), Pastor-Anglada, M. (Marçal)   +8 more
core   +1 more source

Purine nucleoside phosphorylase activity in acute lymphoblastic leukemia [PDF]

Blood, 1980
Purine nucleoside phosphorylase (PNP) activity has been measured in the lymphoblasts of 22 patients with acute lymphoblastic leukemia (ALL) and correlated with routine immunologic cell surface markers. Fourteen of the 22 patients were considered to have non-T, non-B-cell ALL; 8 patients had T-cell disease.
Neil Levin, Gregory H. Reaman, Julie Blatt, David G. Poplack   +3 more
openaire   +4 more sources

Extracellular ATP: an emerging multifaceted regulator of plant fitness

Plant Biotechnology Journal, Volume 23, Issue 5, Page 1771-1782, May 2025.
Summary Adenosine 5′‐triphosphate (ATP) is the energy currency of living organisms and the primary form of organic phosphate (Po) involved in cellular metabolism. In plants, some ATP is released into the extracellular matrix (ECM) in response to various stimuli, where it functions as extracellular ATP (eATP), a key signalling molecule.
De Peng Yuan, Daewon Kim, Yuan Hu Xuan
wiley   +1 more source